uk 68798 has been researched along with cisapride in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Chen, XL; Hendrix, J; Kang, J; Korolev, AM; Lysenkova, LN; Miroshnikova, OV; Pearlstein, RA; Preobrazhenskaya, M; Rampe, D; Shchekotikhin, AE; Vaz, RJ | 1 |
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Bianucci, AM; Calderone, V; Coi, A; Massarelli, I; Testai, L | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Brown, AM; Dennis, A; Rampe, D; Roy, ML | 1 |
| Adamantidis, MM; Bastide, M; Dumotier, BM | 1 |
| Alexander, P; Davie, C; Mitcheson, J; Pierre-Valentin, J; Pollard, C; Standen, N; Thong, B | 1 |
| Hamlin, RL; Keene, BW; Kijtawornrat, A; Nishijima, Y; Roche, BM | 1 |
| Hamlin, RL; Kijtawornrat, A; Sawangkoon, S | 1 |
| Abi-Gerges, N; Boyett, MR; Davies, MR; Di Veroli, GY; Zhang, H | 1 |
| Clancy, CE; Romero, L; Saiz, J; Trenor, B; Yang, PC | 1 |
| Gardner, A; Sanguinetti, MC; Wu, W | 1 |
| Casarotto, E; Danhof, M; Della Pasqua, O; Dubois, VF | 1 |
21 other study(ies) available for uk 68798 and cisapride
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.
Topics: Amino Acids, Aromatic; Cation Transport Proteins; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Imidazoles; Indoles; Inhibitory Concentration 50; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship; Structural Homology, Protein; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation.
Topics: Amino Acid Sequence; Heart; Humans; Models, Molecular; Molecular Sequence Data; Molecular Structure; Protein Subunits; Sequence Alignment; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
Topics: Arrhythmias, Cardiac; Cation Transport Proteins; Cell Line; Cisapride; DNA-Binding Proteins; Electrophysiology; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Heart; Humans; Kv1.5 Potassium Channel; Myocardium; Patch-Clamp Techniques; Phenethylamines; Piperidines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Sulfonamides; Terfenadine; Trans-Activators; Transcriptional Regulator ERG; Transfection; Tumor Cells, Cultured | 1997 |
"Use-dependent" effects of cisapride on postrest action potentials in rabbit ventricular myocardium.
Topics: 4-Aminopyridine; Action Potentials; Animals; Anti-Arrhythmia Agents; Chromans; Cisapride; Dose-Response Relationship, Drug; Electric Stimulation; Heart Ventricles; In Vitro Techniques; Male; Phenethylamines; Piperidines; Rabbits; Sulfonamides; Time Factors; Ventricular Function | 2001 |
Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Topics: Animals; Cation Transport Proteins; Cisapride; Dose-Response Relationship, Drug; Electrophysiologic Techniques, Cardiac; Ether-A-Go-Go Potassium Channels; Guinea Pigs; In Vitro Techniques; Loratadine; Male; Myocytes, Cardiac; Phenethylamines; Potassium Channels, Voltage-Gated; Sulfonamides; Time Factors; Torsades de Pointes | 2004 |
Use of a failing rabbit heart as a model to predict torsadogenicity.
Topics: Amiodarone; Animals; Cardiac Output, Low; Cisapride; Dose-Response Relationship, Drug; Electrocardiography; Models, Animal; Phenethylamines; Quaternary Ammonium Compounds; Quinidine; Rabbits; Sulfonamides; Torsades de Pointes; Verapamil | 2006 |
Assessment of QT-prolonging drugs in the isolated normal and failing rabbit hearts.
Topics: Animals; Arrhythmias, Cardiac; Cisapride; Electrocardiography; Feasibility Studies; Glucose; Heart; Heart Failure; In Vitro Techniques; Male; Models, Animal; Phenethylamines; Quinidine; Rabbits; Sulfonamides; Torsades de Pointes; Tromethamine | 2012 |
High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Topics: Action Potentials; Animals; CHO Cells; Cisapride; Computer Simulation; Cricetinae; Cricetulus; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; High-Throughput Screening Assays; Humans; Kinetics; Long QT Syndrome; Markov Chains; Models, Cardiovascular; Patch-Clamp Techniques; Phenethylamines; Potassium Channel Blockers; Propanolamines; Protein Binding; Risk Assessment; Sulfonamides; Torsades de Pointes; Toxicity Tests; Transfection | 2013 |
In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
Topics: Action Potentials; Anti-Arrhythmia Agents; Astemizole; Cisapride; Computer Simulation; Gene Expression; Genetic Predisposition to Disease; Heart Ventricles; Humans; Ion Channel Gating; Kinetics; Long QT Syndrome; Models, Statistical; Mutation; Phenethylamines; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Protein Conformation; Severity of Illness Index; Sotalol; Sulfonamides; Terfenadine | 2014 |
The Link between Inactivation and High-Affinity Block of hERG1 Channels.
Topics: Animals; Benzopyrans; Cisapride; Ether-A-Go-Go Potassium Channels; Female; Humans; Ion Channel Gating; Oocytes; Patch-Clamp Techniques; Phenethylamines; Piperidines; Point Mutation; Potassium Channel Blockers; Protein Multimerization; Protein Subunits; Sulfonamides; Xenopus laevis | 2015 |
Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies.
Topics: Animals; Binding Sites; Cells, Cultured; Cisapride; Consciousness; Dogs; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Long QT Syndrome; Male; Models, Animal; Models, Biological; Moxifloxacin; Phenethylamines; Structure-Activity Relationship; Sulfonamides | 2016 |